Early versus delayed bilateral subthalamic deep brain stimulation for Parkinson's disease: A decision analysis

Movement Disorders

Volumn 25, Issue 10, 2010, Pages 1456-1463

  Espay, Alberto J ^a   Vaughan, Jennifer E ^a   Marras, Connie ^b,c   Fowler, Rob ^d   Eckman, Mark H ^e  

^a UNIVERSITY OF CINCINNATI   (United States)

^b TORONTO WESTERN HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

Decision analysis; Markov; Monte Carlo simulation; Parkinson's disease; Subthalamic deep brain stimulation; Utilities

Indexed keywords

ADULT; AGED; ARTICLE; BRAIN DEPTH STIMULATION; CLINICAL ARTICLE; COGNITION; DISEASE COURSE; FEMALE; HUMAN; MALE; MONTE CARLO METHOD; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SUBTHALAMIC NUCLEUS;

AGED; ANTIPARKINSON AGENTS; COGNITION DISORDERS; DECISION SUPPORT TECHNIQUES; DEEP BRAIN STIMULATION; FEMALE; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; PARKINSON DISEASE; QUALITY OF LIFE; SUBTHALAMIC NUCLEUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77955000569     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23111     Document Type: Article

References (51)

1. Limousin P, Pollak P, Benazzouz A, et al. Bilateral subthalamic nucleus stimulation for severe Parkinson's disease. Mov Disord 1995;10:672-674. (Pubitemid 23126192)
2. Herzog J, Volkmann J, Krack P, et al. Two-year follow-up of subthalamic deep brain stimulation in Parkinson's disease. Mov Disord 2003;18:1332-1337. (Pubitemid 38263319)
3. Kleiner-Fisman G, Fisman DN, Sime E, Saint-Cyr JA, Lozano AM, Lang AE. Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg 2003;99:489-495. (Pubitemid 37040409)
4. Rodriguez-Oroz MC, Zamarbide I, Guridi J, Palmero MR, Obeso JA. Efficacy of deep brain stimulation of the subthalamic nucleus in Parkinson's disease 4 years after surgery: double blind and open label evaluation. J Neurol Neurosurg Psychiatry 2004;75:1382-1385.
5. Pinter MM, Alesch F, Murg M, Seiwald M, Helscher RJ, Binder H. Deep brain stimulation of the subthalamic nucleus for control of extrapyramidal features in advanced idiopathic parkinson's disease: one year follow-up. J Neural Transm 1999;106:693-709. (Pubitemid 29401357)
6. Defer GL, Widner H, Marie RM, Remy P, Levivier M. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord 1999;14:572-584. (Pubitemid 30011449)
7. Morgante L, Morgante F, Moro E, et al. How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. Parkinsonism Relat Disord 2007;13:528-531.
8. Schupbach M, Gargiulo M, Welter ML, et al. Neurosurgery in Parkinson disease: a distressed mind in a repaired body? Neurology 2006;66:1811-1816.
9. Lang AE, Widner H. Deep brain stimulation for Parkinson's disease: patient selection and evaluation. Mov Disord 2002;17(Suppl 3):S94-S101.
10. Volkmann J. Deep brain stimulation for the treatment of Parkinson's disease. J Clin Neurophysiol 2004;21:6-17. (Pubitemid 38507109)
11. Kleiner-Fisman G, Herzog J, Fisman DN, et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 2006;21 (Suppl 14):S290-S304.
12. Schupbach WM, Maltete D, Houeto JL, et al. Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial. Neurology 2007;68:267-271.
13. Charles PD. Deep brain stimulation for early stage parkinson's disease. ClinicalTrials gov 2008ClinicalTrials.gov Identifier: NCT00282152. Available at http://clinicaltrials.gov/ct2/show/NCT00282152.
14. Deuschl G; German Parkinson Study Group (GPS). Controlled trial of deep brain stimulation in early patients with Parkinson's disease. ClinicalTrials gov 2008ClinicalTrials.gov Identifier: NCT00354133. Available at http://clinicaltrials.gov/ct2/show/NCT00354133.
15. Brauer CA, Bozic KJ. Using observational data for decision analysis and economic analysis. J Bone Joint Surg Am 2009;91 (Suppl 3): 73-79.
16. Inadomi JM. Decision analysis and economic modelling: a primer. Eur J Gastroenterol Hepatol 2004;16:535-542.
17. Umemura A, Jaggi JL, Hurtig HI, et al. Deep brain stimulation for movement disorders: morbidity and mortality in 109 patients. J Neurosurg 2003;98:779-784.
18. Lyons KE, Wilkinson SB, Overman J, Pahwa R. Surgical and hardware complications of subthalamic stimulation: a series of 160 procedures. Neurology 2004;63:612-616.
19. Beric A, Kelly PJ, Rezai A, et al. Complications of deep brain stimulation surgery. Stereotact Funct Neurosurg 2001;77:73-78.
20. Jaggi JL, Umemura A, Hurtig HI, et al. Bilateral stimulation of the subthalamic nucleus in Parkinson's disease: surgical efficacy and prediction of outcome. Stereotact Funct Neurosurg 2004;82:104-114.
21. Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol 2001;58:1611-1615.
22. Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Progression of motor impairment and disability in Parkinson disease: a population-based study. Neurology 2005;65:1436-1441.
23. Hilker R, Schweitzer K, Coburger S, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 2005;62:378-382.
24. Galvin JE. Cognitive change in Parkinson disease. Alzheimer Dis Assoc Disord 2006;20:302-310.
25. Anderson KE. Dementia in Parkinson's disease. Curr Treat Options Neurol 2004;6:201-207.
26. Office of Vital Records and Statistics (VRS). Utah's Vital Statistics - Births and Deaths 2002. Salt Lake City, Utah; 2004. Report No.: 225.
27. Factor SA, Feustel PJ, Friedman JH, et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 2003;60:1756-1761.
28. Schrag A, Ben Shlomo Y, Brown R, Marsden CD, Quinn N. Young-onset Parkinson's disease revisited - clinical features, natural history, and mortality. Mov Disord 1998;13:885-894.
29. Vingerhoets FJ, Villemure JG, Temperli P, Pollo C, Pralong E, Ghika J. Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up. Neurology 2002;58:396-401.
30. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making 1985;5:157-177.
31. Critchfield GC, Willard KE, Connelly DP. Probabilistic sensitivity analysis methods for general decision models. Comput Biomed Res 1986;19:254-265.
32. Martin AJ, Glasziou PP, Simes RJ, Lumley T. A comparison of standard gamble, time trade-off, and adjusted time trade-off scores. Int J Technol Assess Health Care 2000;16:137-147.
33. Stiggelbout AM, Kiebert GM, Kievit J, Leer JW, Habbema JD, De Haes JC. The "utility" of the time trade-off method in cancer patients: feasibility and proportional trade-off. J Clin Epidemiol 1995;48:1207-1214.
34. Gonzalez EF, Eckman MH, Pauker SG. "Gambler": a computer workstation for patient utility assessment. Med Decis Making 1992;12:350.
35. Fryback DG, Lawrence WF, Martin PA, Klein R, Klein BE. Predicting quality of well-being scores from the SF-36: results from the Beaver Dam Health Outcomes Study. Med Decis Making 1997;17:1-9.
36. Marsden CD, Parkes JD. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976;1:292-296.
37. Palmer CS, Schmier JK, Snyder E, Scott B. Patient preferences and utilities for "off-time" outcomes in the treatment of Parkinson's disease. Qual Life Res 2000;9:819-827.
38. Verbaan D, Marinus J, Visser M, et al. Cognitive impairment in Parkinson's disease. J Neurol Neurosurg Psychiatry 2007;78:1182-1187.
39. Krause M, Fogel W, Mayer P, Kloss M, Tronnier V. Chronic inhibition of the subthalamic nucleus in Parkinson's disease. J Neurol Sci 2004;219:119-124.
40. Hilker R, Portman AT, Voges J, et al. Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation. J Neurol Neurosurg Psychiatry 2005;76:1217-1221.
41. Aybek S, Gronchi-Perrin A, Berney A, et al. Long-term cognitive profile and incidence of dementia after STN-DBS in Parkinson's disease. Mov Disord 2007;22:974-981.
42. Oh MY, Abosch A, Kim SH, Lang AE, Lozano AM. Long-term hardware-related complications of deep brain stimulation. Neurosurgery 2002;50:1268-1274.
43. Kassirer JP, Pauker SG. The toss-up. N Engl J Med 1981;305:1467-1469.
44. Derost PP, Ouchchane L, Morand D, et al. Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population? Neurology 2007;68:1345-1355.
45. Spottke EA, Volkmann J, Lorenz D, et al. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus. J Neurol 2002;249:759-766.
46. Meissner W, Schreiter D, Volkmann J, et al. Deep brain stimulation in late stage Parkinson's disease: a retrospective cost analysis in Germany. J Neurol 2005;252:218-223.
47. Tomaszewski KJ, Holloway RG. Deep brain stimulation in the treatment of Parkinson's disease: a cost-effectiveness analysis. Neurology 2001;57:663-671.
48. Valldeoriola F, Morsi O, Tolosa E, Rumia J, Marti MJ, Martinez-Martin P. Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease. Mov Disord 2007;22:2183-2191.
49. Fraix V, Houeto JL, Lagrange C, et al. Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson's disease. J Neurol Neurosurg Psychiatry 2006;77:443-449.
50. Mulley AG. The Role of Decision Analysis in the Translation of Research Findings into Clinical Practice. In: Gelijns AC, editor. Modern Methods of Clinical Investigation. Washington, DC: National Academy Press; 1990. p. 78-87
51. Movement Disorders Society Task Force for Rating Scales for Parkinson's Disease. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 2003;18:738-750.